EP1259236A4 - Tyrosine kinase inhibitors - Google Patents

Tyrosine kinase inhibitors

Info

Publication number
EP1259236A4
EP1259236A4 EP01914424A EP01914424A EP1259236A4 EP 1259236 A4 EP1259236 A4 EP 1259236A4 EP 01914424 A EP01914424 A EP 01914424A EP 01914424 A EP01914424 A EP 01914424A EP 1259236 A4 EP1259236 A4 EP 1259236A4
Authority
EP
European Patent Office
Prior art keywords
tyrosine kinase
kinase inhibitors
inhibitors
tyrosine
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01914424A
Other languages
German (de)
French (fr)
Other versions
EP1259236A1 (en
Inventor
Mark E Fraley
George D Hartman
Randall W Hungate
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1259236A1 publication Critical patent/EP1259236A1/en
Publication of EP1259236A4 publication Critical patent/EP1259236A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP01914424A 2000-02-25 2001-02-21 Tyrosine kinase inhibitors Withdrawn EP1259236A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18502400P 2000-02-25 2000-02-25
US185024P 2000-02-25
PCT/US2001/005567 WO2001062252A1 (en) 2000-02-25 2001-02-21 Tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
EP1259236A1 EP1259236A1 (en) 2002-11-27
EP1259236A4 true EP1259236A4 (en) 2004-11-03

Family

ID=22679242

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01914424A Withdrawn EP1259236A4 (en) 2000-02-25 2001-02-21 Tyrosine kinase inhibitors

Country Status (5)

Country Link
EP (1) EP1259236A4 (en)
JP (1) JP2003523390A (en)
AU (1) AU778417B2 (en)
CA (1) CA2400923A1 (en)
WO (1) WO2001062252A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12514A (en) 1999-12-24 2006-05-29 Aventis Pharma Ltd Azaindoles.
ATE448226T1 (en) 2000-09-01 2009-11-15 Novartis Vaccines & Diagnostic AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE
PT1650203E (en) 2000-09-11 2008-05-13 Novartis Vaccines & Diagnostic Process of preparation of benzimidazol-2-yl quinolinone derivatives
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
NZ552335A (en) * 2001-10-25 2008-11-28 Novartis Ag Combinations comprising a selective COX-2 inhibitor and a microtubule interfering agent
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
BR0313743A (en) 2002-08-23 2005-07-05 Chiron Corp Benzimidazole quinolinones and uses of these
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
WO2005037306A1 (en) * 2003-10-17 2005-04-28 Novo Nordisk A/S Combination therapy
KR101167573B1 (en) 2003-11-07 2012-07-30 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
WO2006071035A1 (en) * 2004-12-31 2006-07-06 Lg Life Sciences, Ltd. Novel ([1,3]thiazolo[5,4-b]pyridin-2-yl)-2-carboxamide derivatives
ATE526025T1 (en) 2005-01-27 2011-10-15 Novartis Vaccines & Diagnostic TREATMENT OF METASTASIZED TUMORS
JP5545925B2 (en) 2005-05-17 2014-07-09 ノバルティス アーゲー Method for synthesizing heterocyclic compounds
GB0614471D0 (en) 2006-07-20 2006-08-30 Syngenta Ltd Herbicidal Compounds
JP2011513488A (en) * 2008-03-10 2011-04-28 サノフィ−アベンティス Treatment of eye related disorders
CA2897651C (en) 2013-01-10 2021-09-21 Pulmokine, Inc. Non-selective kinase inhibitors
CA2926793C (en) 2013-10-11 2022-11-22 Lawrence S. ZISMAN Spray-dry formulations for treating pulmonary arterial hypertension
CA3041679A1 (en) 2016-10-27 2018-05-03 Lawrence S. ZISMAN Combination therapy for treating pulmonary hypertension

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062251A1 (en) * 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020642A1 (en) * 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062251A1 (en) * 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO0162252A1 *

Also Published As

Publication number Publication date
CA2400923A1 (en) 2001-08-30
JP2003523390A (en) 2003-08-05
WO2001062252A1 (en) 2001-08-30
AU778417B2 (en) 2004-12-02
EP1259236A1 (en) 2002-11-27
AU3981401A (en) 2001-09-03

Similar Documents

Publication Publication Date Title
EG24381A (en) Tyrosine kinase inhibitors
EP1161433A4 (en) Tyrosine kinase inhibitors
AU3704101A (en) Kinase inhibitors
EP1381598A4 (en) Novel tyrosine kinase inhibitors
HK1049154A1 (en) 2-pyrazolin-5-ones as tyrosine kinase inhibitors
AU2003299651A8 (en) Tyrosine kinase inhibitors
SG129306A1 (en) Quinolinone derivatives as tyrosine kinase inhibitors
AU2001237041A1 (en) Kinase inhibitors
AU2002361577A1 (en) Tyrosine kinase inhibitors
AU2003298942A8 (en) Tyrosine kinase inhibitors
EP1534268A4 (en) Tyrosine kinase inhibitors
EP1259236A4 (en) Tyrosine kinase inhibitors
AU2003275282A8 (en) Novel tyrosine kinase inhibitors
AU2002348394A1 (en) Tyrosine kinase inhibitors
AU2002348020A1 (en) Tyrosine kinase inhibitors
AU2002348393A1 (en) Tyrosine kinase inhibitors
EP1496897A4 (en) Tyrosine kinase inhibitors
AU2002323406A1 (en) Tyrosine kinase inhibitors
AU2002327534A1 (en) Tyrosine kinase inhibitors
GB0201384D0 (en) Tyrosine kinase inhibitors
GB0013807D0 (en) Tyrosine kinase modulators
IL145329A0 (en) Protein tyrosine kinase inhibitors
AU2002322568A1 (en) Tyrosine kinase inhibitors
AU2002326760A1 (en) Tyrosine kinase inhibitors
AU2002326865A1 (en) Tyrosine kinase inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020925

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL PAYMENT 20020925;LT PAYMENT 20020925;LV PAYMENT 20020925;MK PAYMENT 20020925;RO PAYMENT 20020925;SI PAYMENT 20020925

A4 Supplementary search report drawn up and despatched

Effective date: 20040921

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07D 519/00 B

Ipc: 7A 61K 31/4355 A

Ipc: 7C 07D 209:00 J

Ipc: 7A 61K 31/437 B

Ipc: 7A 61P 35/00 B

Ipc: 7A 61K 31/4375 B

Ipc: 7C 07D 471/04 B

Ipc: 7A 61K 31/4365 B

Ipc: 7C 07D 471/04 J

Ipc: 7C 07D 221:00 J

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HUNGATE, RANDALL, W.

Inventor name: HARTMAN, GEORGE, D.

Inventor name: FRALEY, MARK, E.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4355 20060101AFI20070227BHEP

Ipc: C07D 221/00 20060101ALN20070227BHEP

Ipc: A61P 35/00 20060101ALI20070227BHEP

Ipc: A61K 31/4365 20060101ALI20070227BHEP

Ipc: A61K 31/437 20060101ALI20070227BHEP

Ipc: C07D 471/04 20060101ALI20070227BHEP

Ipc: C07D 519/00 20060101ALI20070227BHEP

Ipc: A61K 31/4375 20060101ALI20070227BHEP

Ipc: C07D 209/00 20060101ALN20070227BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070724